^
CANCER:

Vulvar Cancer

PD-L1 expression
Vulvar Cancer
pembrolizumab
Sensitive: A2 - Guideline
NTRK3 fusion
Vulvar Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Vulvar Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Vulvar Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Vulvar Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Vulvar Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Vulvar Cancer
larotrectinib
Sensitive: A2 - Guideline
No biomarker
Vulvar Cancer
nivolumab
Sensitive: A2 - Guideline
MSI-H/dMMR
Vulvar Cancer
pembrolizumab
Sensitive: A2 - Guideline
TMB-H
Vulvar Cancer
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Vulvar Cancer
GC
Sensitive: A2 - Guideline
No biomarker
Vulvar Cancer
erlotinib
Sensitive: A2 - Guideline
No biomarker
Vulvar Cancer
cisplatin + vinorelbine
Sensitive: A2 - Guideline
No biomarker
Vulvar Cancer
paclitaxel
Sensitive: A2 - Guideline
No biomarker
Vulvar Cancer
bevacizumab
Sensitive: A2 - Guideline
No biomarker
Vulvar Cancer
CP
Sensitive: A2 - Guideline
No biomarker
Vulvar Cancer
CaT
Sensitive: A2 - Guideline
No biomarker
Vulvar Cancer
carboplatin
Sensitive: A2 - Guideline
No biomarker
Vulvar Cancer
FP
Sensitive: A2 - Guideline
No biomarker
Vulvar Cancer
cisplatin
Sensitive: A2 - Guideline
No biomarker
Vulvar Cancer
5-fluorouracil + mitomycin
Sensitive: A2 - Guideline
PD-L1 negative
Vulvar Cancer
pembrolizumab
Sensitive: C3 – Early Trials
PD-L1 overexpression
Vulvar Cancer
pembrolizumab
Sensitive: C4 – Case Studies